Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash from Financing Activities (2017 - 2025)

Arcus Biosciences has reported Cash from Financing Activities over the past 9 years, most recently at $286.0 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $286.0 million for Q4 2025, up 14400.0% from a year ago — trailing twelve months through Dec 2025 was $488.0 million (up 76.17% YoY), and the annual figure for FY2025 was $488.0 million, up 76.17%.
  • Cash from Financing Activities for Q4 2025 was $286.0 million at Arcus Biosciences, up from $8.0 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for RCUS hit a ceiling of $286.0 million in Q4 2025 and a floor of -$2.0 million in Q4 2024.
  • Median Cash from Financing Activities over the past 5 years was $9.5 million (2022), compared with a mean of $53.4 million.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 36313.11% in 2021 and later plummeted 166.67% in 2024.
  • Arcus Biosciences' Cash from Financing Activities stood at $11.3 million in 2021, then decreased by 2.92% to $11.0 million in 2022, then tumbled by 72.73% to $3.0 million in 2023, then crashed by 166.67% to -$2.0 million in 2024, then surged by 14400.0% to $286.0 million in 2025.
  • The last three reported values for Cash from Financing Activities were $286.0 million (Q4 2025), $8.0 million (Q3 2025), and $52.0 million (Q2 2025) per Business Quant data.